IELSG Annual Meeting 2026
Bellinzona, March 6-7, 2026

Auditorium Bellinzona
Istituto Cantonale di Economia e Commercio | Viale Stefano Franscini 32 | 6501 Bellinzona (Switzerland)

CLOSED MEETINGS | Friday, March 6, 2026

09:30-10:30 Online only	Toward a Pan-European front-line clinical trial in PCNSL?	11:00-12:00 Hybrid	IELSG early-phase clinical trials in lymphoma Institute of Oncology Research (IOR) Via Francesco Chiesa 5 | Bellinzona

Day 1	**Friday, March 6, 2026**	Institute of Oncology Research (IOR) Via Francesco Chiesa 5 | Bellinzona
10:30-11:45	Visit to the Institute of Oncology Research	Online registration required
		Auditorium Bellinzona - Foyer
12:00-13:30	Standing Lunch	Online registration required
13:00-13:30	Meeting registration	Auditorium Bellinzona - Foyer
13:30-13:40	**Welcome and Introductory Remarks**	**Emanuele Zucca**
13:40-14:10	**Educational Lecture**	
13:40	Current landscape of Burkitt Lymphoma	Martine Chamuleau
14:10-14:55	**Primary Mediastinal B-Cell Lymphoma (PMBCL)**	**Chair: Alice Di Rocco**
14:10	IELSG37 – Additional studies and manuscript preparation on PMBCL	Luca Ceriani
14:25	IELSG55 – RWD analysis of R-CHOP 14 efficacy in the first-line treatment of PMBCL	Anna Dabrowska and Vincent Camus
14:40	IELSG51 – Assessing a PET and ctDNA-guided first-line de-escalation therapy in patients with PMBCL: A multicenter, phase III non-inferiority trial	Anastasios Stathis
14:55-16:10	**Marginal Zone Lymphoma I**	**Chair: Luca Arcaini**
14:55	IELSG39 – First-line *C. Psitacci*-eradicating therapy with protracted doxycycline in Ocular Adnexal MZL: ancillary studies	Maurilio Ponzoni
15:10	IELSG44 – PIMENTO – FDG-PET evaluation for MZL and its prognostic role: an international multicenter retrospective analysis – study results	Luca Ceriani
15:25	IELSG47 – MALIBU – Phase II study of ibrutinib and rituximab in untreated MZL: Preliminary results	Annarita Conconi
15:40	IELSG49 – Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated MZL	Anastasios Stathis
15:55	Drug resistance extranodal lymphomas: lab clues to new therapies	Francesco Bertoni
16:10-16:40	*Coffee break*	
16:40-18:25	**Primary and Secondary Lymphoma of the Central Nervous System (CNS)**	**Chair: Teresa Calimeri and Diva Baggio**
16:40	Current treatment approaches for PCNS in China	Li Wang
16:55	1. Update from the German CNS Study Group	Gerald Illerhaus
17:10	2. Prospective observational study on primary vitreoretinal lymphoma	Teresa Calimeri and Benjamin Kasenda
17:25	3. Study on incorporating a BTK inhibitor into the front-line strategy	Andrés Ferreri
17:40	4. A "post-FIORELLA" retrospective data collection	Andrés Ferreri
17:55	5. European survey on CNS prophylaxis	Magdalena Klánová
18:10	IELSG57 – Characterization of primary central nervous system diffuse large B cell lymphoma (PCNS-DLBCL) by multiomic approach	Marco Paulli and Marco Lucioni
18:25	End of day 1	
20:00	Dinner	

	Saturday, March 7, 2026		
07:30-08:30	IELSG Board of Directors	**CLOSED MEETING**	Hotel Internazionale

Day 2	**Saturday, March 7, 2026**	Auditorium Bellinzona
09:15– 11:00	**Marginal Zone Lymphoma II**	**Chair: Annarita Conconi**
09:15	IELSG48 – RITZ - Phase III, interventional, multicentre, open-label, randomized study comparing rituximab plus zanubrutinib to rituximab monotherapy in previously untreated, symptomatic splenic marginal zone lymphoma	Luca Arcaini
09:30	IELSG52 – Integrated molecular and clinical profiling to improve disease characterization and outcome prediction in nodal marginal zone lymphoma	Cristina Pirosa
09:45	IELSG54 – Integrated molecular and clinical profiling of transformed splenic marginal zone lymphoma	Emilia Cappello
10:00	IELSG56 - Molecular and cellular characterization of MALT lymphoma across anatomical sites: integrative transcriptomic and epigenetic approaches	Luciano Cascione
10:15	Update on the Brazilian study on primary extranodal lymphomas (Primary Extranodal Lymphoma Effort - PELE)	Guilherme Duffles
10:30-11:00	*Coffee break*	
11:00-12:00	**General Assembly** **IELSG MEMBERS ONLY**	**Chair: Franco Cavalli**
	Discussion of administrative issues	
12:00	**Closing Remarks**	

Thank you for the unrestricted educational grants

AstraZeneca BeOne abbvie GILEAD Kite Johnson&Johnson Lilly Bristol Myers Squibb Roche Takeda

And for the financial support

Città di Bellinzona



2026 IELSG Annual Meeting
Bellinzona, Switzerland
March 6-7, 2026

IOR IELSG

Auditorium Bellinzona
ICEC - Stabile Torretta
Viale Stefano Franscini 32
6500 Bellinzona

AUDITORIUM BELLINZONA